Corcept Therapeutics price target lowered to $135 from $150 at Truist

finance.yahoo.com/news/corcept-therapeutics-price-target-lowered-140158389.html

In This Article:
Truist analyst Joon Lee lowered the firm’s price target on Corcept Therapeutics (CORT) to $135 from $150 and keeps a Buy rating on the shares. The company’s Q1 Korlym revenue of $157.2M was softer than expected due to bandwidth issues with the pharmacy vendor, the…

This story appeared on finance.yahoo.com, 2025-05-07 14:01:58.
The Entire Business World on a Single Page. Free to Use →